66. IgA nephropathy Clinical trials / Disease details
Clinical trials : 255 / Drugs : 255 - (DrugBank : 79) / Drug target genes : 35 - Drug target pathways : 137
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02662283 (ClinicalTrials.gov) | May 2016 | 20/1/2016 | Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy | Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy —— A Prospective, Randomized, Controlled, Multi-Center Clinical Trial | IGA Nephropathy | Drug: Prednisolone;Drug: Reh-acteoside | Sun Yat-sen University | NULL | Not yet recruiting | 14 Years | 70 Years | Both | 75 | Phase 2/Phase 3 | China |